Profil
Pieter de Geus currently works at Prothya Biosolutions Belgium BV, as Director from 2020, Alveron Pharma BV, as Member-Supervisory Board, and Neuroplast BV, as Member-Supervisory Board from 2021.
Aktive Positionen von Pieter de Geus
Unternehmen | Position | Beginn |
---|---|---|
Neuroplast BV
Neuroplast BV BiotechnologyHealth Technology Neuroplast BV is a Dutch stem cell technology company that focuses on developing autologous cell products for the treatment of primarily inflammation-driven neurological disorders. Neuroplast is located in Brightlands Chemelot Campus in the Netherlands. The company's transformative treatment, Neuro-cellsò, is currently being tested for traumatic spinal cord injury (TSCI) and aims to reduce the irreversible impact of TSCI during the crucial first phase. The company was founded in August 2014 by physician De Munter and neurologist Erik Wolters, and current investors include Invest, Brightlands Venture Partners, and Liof NV. Johannes de Munter has been the CEO of the company since 2016. | Direktor/Vorstandsmitglied | 21.10.2021 |
Alveron Pharma BV
Alveron Pharma BV Pharmaceuticals: MajorHealth Technology Alveron Pharma BV is a Dutch company that develops cyclodextrin-based drugs. The company is based in Nijmegen, Netherlands. The company was founded in 2019. Ben Nichols has been the CEO of the company since 2019. | Direktor/Vorstandsmitglied | - |
Prothya Biosolutions Belgium BV
Prothya Biosolutions Belgium BV BiotechnologyHealth Technology Prothya Biosolutions Belgium BV is a Belgian company that was founded in 1997. The private company is based in Brussels, Belgium. The company manufactures plasma and pharmaceutical raw materials and operate as blood transfusion centers and organ banks. | Direktor/Vorstandsmitglied | 31.12.2020 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Neuroplast BV
Neuroplast BV BiotechnologyHealth Technology Neuroplast BV is a Dutch stem cell technology company that focuses on developing autologous cell products for the treatment of primarily inflammation-driven neurological disorders. Neuroplast is located in Brightlands Chemelot Campus in the Netherlands. The company's transformative treatment, Neuro-cellsò, is currently being tested for traumatic spinal cord injury (TSCI) and aims to reduce the irreversible impact of TSCI during the crucial first phase. The company was founded in August 2014 by physician De Munter and neurologist Erik Wolters, and current investors include Invest, Brightlands Venture Partners, and Liof NV. Johannes de Munter has been the CEO of the company since 2016. | Health Technology |
Alveron Pharma BV
Alveron Pharma BV Pharmaceuticals: MajorHealth Technology Alveron Pharma BV is a Dutch company that develops cyclodextrin-based drugs. The company is based in Nijmegen, Netherlands. The company was founded in 2019. Ben Nichols has been the CEO of the company since 2019. | Health Technology |
Prothya Biosolutions Belgium BV
Prothya Biosolutions Belgium BV BiotechnologyHealth Technology Prothya Biosolutions Belgium BV is a Belgian company that was founded in 1997. The private company is based in Brussels, Belgium. The company manufactures plasma and pharmaceutical raw materials and operate as blood transfusion centers and organ banks. | Health Technology |